An investor continues Unitedhealth Group, accusing the company of having deceived the shareholders by not revealing how he would be affected by the backlash after the murder of the CEO of Unitedhealthcare, Brian Thompson.
Thompson, 50, was killed to death in front of a Manhattan hotel on December 4. Since the arrest of his accused killer, Luigi Mangione, on December 9, the graduate of the Ivy League, 27, cultivated a massive audience when he faced state and federal accusations in the death of Thompson.
US prosecutor Pam Bondi said prosecutors asked for the death penalty in the federal mangione case. He continues to obtain support, his legal defense fund funded by the financing of the crowd exceeding $ 1 million on Tuesday.
However, while Mangione received public support, Unitedhealthcare and other health insurers were examined after the murder of Thompson, many criticizing the American health system as a whole.
In addition to the public counterpoup, Unitedhealthcare was also faced with a meticulous examination of the American Senate, which highlighted the refusal of the company in the weeks preceding the murder of Thompson, according to the trial brought by investor Roberto Faller on Wednesday.
“Following the murder of Mr. Thompson, the reaction was not uniformly
Sympathetic to Mr. Thompson, who was a father, ”read the trial.
Faller’s trial filed in the South New York district noted that on December 3, one day before the murder of Thompson, Unitedhealth Group provided for a net gain of $ 29.50 to $ 30.00 per share.
But the company never told investors how it planned to adjust its strategy following the murder of Thompson to take into account the public reaction and the government’s examination, according to the trial. As of January 16, Unitedhealth Group announced that it would reaffirm the December projections, which, according to Faller, was considerably false and misleading because the company was no longer ready to “use aggressive and anti-consuming tactics” to achieve its profits.
By April, Unitedhealth Group announced that it would move its strategy by allowing coverage and increased care for health insurance beneficiaries. The equity prices of the health insurance company fell by around 22% after the announcement.
Faller’s trial is looking for a certification of collective appeal and unpertified damages for shareholders who bought shares from the United Health group between December 3, 2024 and April 16, 2025.
Unitedhealth Group did not immediately respond to a request for comments from HuffPost but said NBC News that “society denies any allegation of reprehensible acts and intends to defend the question vigorously”.
